Compare Summit Therapeutics Inc (SMMT) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Target Corporation — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while Target Corporation trades at $158.01 (market cap $71.56B). The key difference: Target Corporation is far larger — about 5.1× Summit Therapeutics Inc's market cap, and Target Corporation pays a 2.95% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TGT | |
|---|---|---|
Market Cap | $13.98B | $71.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $169.90 |
52-Week Low | $12.43 | $83.68 |
Enterprise Value | $13.31B | $84.84B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Target (TGT) trades at $162.71, down 1.05% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly EPS beats. Revenue remains stable near $107B, while valuation ratios like P/E of 16.88 and P/S of 0.69 suggest reasonable pricing. Recent news highlights CEO Michael Fiddelke's turnaround success, with shares surging over 70% year-to-date.
Outlook is positive with analyst consensus at $166.67 and 47% buy ratings, but risks include competitive retail pressures and margin compression. The dividend yield of approximately 2.85% adds income appeal, though valuation expansion from recent gains warrants caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
